Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aleta Biotherapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Aleta Biotherapeutics

Aleta Biotherapeutics

Series A

Aleta Biotherapeutics: Pioneering immuno-oncology cellular therapies for diverse cancer types since 2015.

HQ
Natick, MA, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Aleta Biotherapeutics, founded in 2015 and headquartered in Natick, Massachusetts, is an immuno-oncology company dedicated to transforming cellular therapeutics to target a broader spectrum of cancer indications. The company focuses on developing novel engager proteins that enhance the efficacy of CAR-T cells, enabling them to effectively kill targeted tumor cells. Aleta’s core mission is to pioneer innovative treatments that address unmet needs in cancer therapy, with a vision of making advanced cellular therapies accessible to more patients.

Notable figures associated with Aleta Biotherapeutics include experienced leaders in biotechnology and oncology. The company has garnered attention from prominent investors in the biotech sector, contributing to its growth and development. Key achievements include advancing their CAR T Engagers (CTEs) through preclinical and clinical stages, demonstrating significant potential in treating lymphoma and myeloma. Aleta Biotherapeutics' impact lies in its cutting-edge approach to enhancing CAR-T cell therapies, offering hope for more effective cancer treatments.

Aleta Biotherapeutics - Quick Facts

When was Aleta Biotherapeutics founded?

Aleta Biotherapeutics was founded in 2015.

Where is Aleta Biotherapeutics' headquarters located?

Aleta Biotherapeutics' headquarters is located in Natick, MA, US.

When was Aleta Biotherapeutics' last funding round?

Aleta Biotherapeutics' most recent funding round was for $13.7M (USD) in July 2021.

How much has Aleta Biotherapeutics raised to-date?

As of Jul 16, 2021, Aleta Biotherapeutics has raised a total of $13.7M (USD).

How many employees does Aleta Biotherapeutics have?

Aleta Biotherapeutics has 7 employees as of Feb 5, 2024.

Aleta Biotherapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cellular Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified